Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

Johnson & Johnson and Novartis are effectively managing significant patent cliffs for key drugs Stelara and Entresto, respectively, leveraging their diversified product portfolios and robust innovation pipelines. Despite Stelara's declining sales post-exclusivity, J&J reported overall revenue growth and raised guidance, while Novartis anticipates continued high-single-digit revenue growth despite impending generic competition for Entresto. Both companies' resilience, underpinned by strong financial performance and consistent dividend increases, positions them to navigate these challenges and deliver long-term value.

Analysis

Johnson & Johnson (JNJ) and Novartis (NVS) are demonstrating resilience in the face of significant patent expirations for key products. For JNJ, despite Stelara facing biosimilar competition and its Q2 sales declining 42.7% to $1.7 billion, the company's overall revenue grew 5.8% to $23.7 billion, leading to an upward revision of its full-year guidance. This performance is underpinned by a diversified portfolio, including strong growth from cancer drugs Darzalex and Erleada, a robust pipeline featuring newly approved Imaavy and investigational bladder cancer treatment TAR-200, and innovation in its medical device segment with the Ottava surgical robot. Similarly, Novartis is proactively managing the impending U.S. patent cliff for its top-selling heart failure drug, Entresto, which generated $4.6 billion in the first half of the year. The company maintains a high-single-digit revenue growth forecast for the year, supported by a deep portfolio with seven other blockbuster drugs and promising new launches like Vanrafia, which has an estimated peak sales potential of $1.5 billion. Both companies supplement their operational strength with strong capital return programs, with JNJ marking 62 consecutive years of dividend increases and Novartis marking 28, positioning them to navigate these cyclical industry pressures effectively.

Key Decisions for Investors

• Investors should look beyond the headline risk of patent cliffs for Stelara and Entresto, as both J&J and Novartis are effectively mitigating the impact through portfolio diversification and pipeline innovation.
• Monitor the commercial success of new products, such as J&J's Imaavy and Novartis's Vanrafia, and the clinical progress of key pipeline assets like TAR-200, as these are critical to sustaining long-term growth.
• For income-focused investors, the strong and consistent dividend histories of both companies, supported by resilient financial performance, suggest they remain compelling long-term holdings for stable capital returns.
• Keep a close watch on the outcome of Novartis's patent litigation concerning Entresto, as a favorable ruling could provide a financial buffer against losses from generic competition.